Avidity Biosciences, Inc (RNAM) - Total Assets
Based on the latest financial reports, Avidity Biosciences, Inc (RNAM) holds total assets worth $1.96 Billion USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Avidity Biosciences, Inc shareholders equity for net asset value and shareholders' equity analysis.
Avidity Biosciences, Inc - Total Assets Trend (2018–2025)
This chart illustrates how Avidity Biosciences, Inc's total assets have evolved over time, based on quarterly financial data.
Avidity Biosciences, Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Avidity Biosciences, Inc's total assets of $1.96 Billion consist of 91.9% current assets and 8.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 19.5% |
| Accounts Receivable | $12.44 Million | 0.6% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2025)
This chart illustrates how Avidity Biosciences, Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Avidity Biosciences, Inc market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Avidity Biosciences, Inc's current assets represent 91.9% of total assets in 2025, an increase from 81.4% in 2018.
- Cash Position: Cash and equivalents constituted 19.5% of total assets in 2025, down from 77.6% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is accounts receivable at 0.6% of total assets.
Avidity Biosciences, Inc Competitors by Total Assets
Key competitors of Avidity Biosciences, Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
GlycoMimetics Inc
NASDAQ:GLYC
|
USA | $5.99 Billion |
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Samsung Biologics Co Ltd
KO:207940
|
Korea | ₩18.34 Trillion |
|
Royalty Pharma Plc
NASDAQ:RPRX
|
USA | $19.62 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Abivax SA American Depositary Shares
NASDAQ:ABVX
|
USA | $584.09 Million |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
Avidity Biosciences, Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 9.20 | 15.73 | 17.81 |
| Quick Ratio | 9.20 | 15.73 | 17.81 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $1.60 Billion | $1.44 Billion | $294.44 Million |
Avidity Biosciences, Inc - Advanced Valuation Insights
This section examines the relationship between Avidity Biosciences, Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.55 |
| Latest Market Cap to Assets Ratio | 5.63 |
| Asset Growth Rate (YoY) | 25.2% |
| Total Assets | $1.96 Billion |
| Market Capitalization | $11.02 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Avidity Biosciences, Inc's assets at a significant premium (5.63x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Avidity Biosciences, Inc's assets grew by 25.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Avidity Biosciences, Inc (2018–2025)
The table below shows the annual total assets of Avidity Biosciences, Inc from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $1.96 Billion | +25.20% |
| 2024-12-31 | $1.56 Billion | +148.81% |
| 2023-12-31 | $628.55 Million | -1.60% |
| 2022-12-31 | $638.80 Million | +49.40% |
| 2021-12-31 | $427.58 Million | +28.06% |
| 2020-12-31 | $333.90 Million | +244.56% |
| 2019-12-31 | $96.91 Million | +2333.63% |
| 2018-12-31 | $3.98 Million | -- |
About Avidity Biosciences, Inc
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics called antibody oligonucleotide conjugates (AOCs). Its AOC platform is designed to combine the specificity of monoclonal antibodies with the precision of RNA therapeutics to target the root cause of diseases previously untreatable with such therapeutics. The company's pipeline has three programs in… Read more